Effect of Physician Attire on Patients' Preference of Physician

November 11, 2020 updated by: M.D. Anderson Cancer Center

Advanced Cancer Patients' Perception of Physician Compassion and Professionalism - A Randomized, Double Blind, Cross Over Trial

The goal of this research study is to learn about the effects of a doctor's characteristics on participant's preference for a doctor. Researchers also want to learn about how a doctor's characteristics affect participant's options about professionalism and compassion.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

If participant agrees to take part in this study, participant will be asked to complete 7 questionnaires. These questionnaires ask about participant's gender, date of birth, ethnicity, marital status, level of education, religion, and information about the disease and treatments participant received. Participant will also be asked about any symptoms participant may be having, how much trust participant has in the medical profession in general, how participant feels about the disease, any depression or anxiety participant may have, and participant's level of hopefulness. These questionnaires should take about 6 minutes to complete.

Participant will be shown 2 videos (each 3 minutes long) and then participant will complete questions about each video. Participant will be asked to rate the doctors participant saw on their professionalism and their compassion.

Caregivers will be required to leave the room or stay silent while the participant is watching the videos.

The total time to watch the videos and complete the second set of questionnaires should be about 7 minutes.

Finally, participant will be asked to complete 3 questionnaires about participant's overall preference for a doctor. These questionnaires will take about 5 minutes to complete.

Length of Study Participation:

Participation in this study is complete after participant answers the final questionnaires.

Overall, this study should take about 30 minutes to complete.

This is an investigational study.

Up to 108 participants will be enrolled in this study. All will take part at MD Anderson.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
108

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • University of Texas MD Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Advanced cancer diagnosis (locally advanced, recurrent or metastatic disease).
  2. Patients presenting as follow-ups only at the outpatient Supportive Care Center.
  3. Age >/= 18 years-old
  4. English speaking

Exclusion Criteria:

  1. Altered cognition (as assessed routinely in the Supportive Care Clinic using the Memorial Delirium Assessment Scale (MDAS), with a score of >/= 7/30).
  2. Patients suffering from a severe psychiatric disorder or condition that would significantly interfere with study participation.
  3. Patients with hearing and/or visual impairments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Video 1A

Questionnaires completed at baseline, after each video viewing, and at completion.

Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Video
Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Questionnaires
Questionnaires completed at baseline, after each video viewing, and at completion.
Other Names:
  • Surveys
Experimental: Video 1B

Questionnaires completed at baseline, after each video viewing, and at completion.

Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Video
Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Questionnaires
Questionnaires completed at baseline, after each video viewing, and at completion.
Other Names:
  • Surveys
Experimental: Video 2A

Questionnaires completed at baseline, after each video viewing, and at completion.

Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Video
Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Questionnaires
Questionnaires completed at baseline, after each video viewing, and at completion.
Other Names:
  • Surveys
Experimental: Video 2B

Questionnaires completed at baseline, after each video viewing, and at completion.

Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Video
Participants shown Video 1A or 1B, then shown Video 2A or 2B.
Behavioral: Questionnaires
Questionnaires completed at baseline, after each video viewing, and at completion.
Other Names:
  • Surveys

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participant's Perception of Physician's Compassion
Time Frame: 1 day

Participant's rating of physician's compassion assessed by using a validated 5-item tool consisting of five 0-10 numerical rating scales assessing five dimensions: warm-cold, pleasant-unpleasant, compassionate- distant, sensitive- insensitive, and caring-uncaring.

The sum of the five scales gives a final score representing physician's compassion on a scale of 0 to 50.
1 day

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Participant's Perception of Physician's Professionalism
Time Frame: 1 day

Participant's rating of physician's professionalism assessed by using a validated 4-item tool assessing politeness, listening, explaining the condition and treatment to the patient and patient's involvement in treatment decisions. Participant rates from poor-1 to very good-5.

The sum of these 4 items gives a final score representing physician's level of professionalism on a scale of 4 to 20.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
M.D. Anderson Cancer Center

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ahsan Azhar, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 25, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 26, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 26, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 25, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 30, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 13, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 11, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2016-0970
  • NCI-2018-01195 (Registry Identifier: NCI CTRP)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Neoplasms of Independent (Primary) Multiple Sites

Clinical Trials on Video

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings